Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabumetone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.86 |
| ▸ | NPC1 | O15118 | 2/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabumetone SCHEMBL29373228 | 0.93 | CYP1A2 (1.00) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL3853067 | 0.93 | CYP1A2 (1.00) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL29570823 | 0.93 | CYP1A2 (1.00) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL2256 | 0.93 | CYP1A2 (1.00) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL104942 | 0.91 | CYP1A2 (0.97) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL28775077 | 0.91 | CYP1A2 (0.97) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL23064140 | 0.90 | CYP1A2 (0.94) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL1649175 | 0.89 | CYP1A2 (0.81) | RAB9ANPC1MAPTKDM4ELMNA | |
| Nabumetone SCHEMBL7554060 | 0.88 | CYP1A2 (0.91) | RAB9ANPC1MAPTKDM4ELMNA | |
| Benzylacetone SCHEMBL28928562 | 0.88 | ALDH1A1 (0.72) | RAB9ANPC1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | TRPV2, TRPV1, TRPV3 | PTGS2 37/4885RAB9A 4572/4885NPC1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.